Metagenomi
PublicMetagenomi is now publicly traded
The data on this page reflects Metagenomi's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 9, 2024
Last Round
Series B
Extension
Jan 5, 2023
Total Funding Raised
$443.75M
Company Overview
Metagenomi is a biotechnology company that develops a natural microbial community platform to discover next-generation therapeutics by revealing novel cellular machinery from unknown organisms and reconstructing metagenomic ecosystems for breakthrough genome editing systems.
Sector
Biotech
AI Layer
Infrastructure
Keywords
Metagenomi Comparables
Compare Metagenomi with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mammoth Biosciences | 86% | |
| Tessera Therapeutics | 76% | |
| Acrigen Biosciences | 71% |
Metagenomi Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 9, 2024 | ||||
| Series B Extension | Jan 5, 2023 | ||||
| Series B | Jan 25, 2022 | ||||
| Series A Extension | Apr 7, 2021 | ||||
| Series A | Nov 12, 2020 |
Metagenomi Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Agent Capital | Series A Extension, Series A |
| SymBiosis Capital Management | Series B Extension |
| RA Capital Management | Series B, Series A Extension |
| Farallon Capital Management | Series B Extension, Series B |
| Millennium Management | Series B |
| Heartland Healthcare Capital | Series B Extension |
Metagenomi Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access